Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
NASDAQ:CRMD

CorMedix Q1 2026 Earnings Report

CorMedix logo
$7.86 -0.20 (-2.42%)
As of 01:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

CorMedix EPS Results

Actual EPS
N/A
Consensus EPS
$0.35
Beat/Miss
N/A
One Year Ago EPS
N/A

CorMedix Revenue Results

Actual Revenue
N/A
Expected Revenue
$104.96 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

CorMedix Announcement Details

Quarter
Q1 2026
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

CorMedix Earnings Headlines

CorMedix Inc (NASDAQ:CRMD) Given Consensus Recommendation of "Moderate Buy" by Analysts
May 6 at 2:57 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30760778
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
May 5 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287682/0/en/cormedix-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-14-2026.html
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
May 7 at 1:00 AM  |  Profits Run (Ad)
CRMD stock jumps as antifungal drug clears key trial for $2B preventive market
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/crmd-stock-jumps-as-antifungal-drug-clears-key-trial-for-2b-preventive-market/ar-AA21R9Ao
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic ...
April 27, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cormedix-therapeutics-announces-positive-topline-results-from-phase-iii-respect-trial-assessing-rezzayo-for-the-prophylaxis-of-invasive-fungal-diseases-in-allogeneic-hematopoietic-stem-cell-1036065988
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3281520/0/en/cormedix-therapeutics-announces-positive-topline-results-from-phase-iii-respect-trial-assessing-rezzayo-for-the-prophylaxis-of-invasive-fungal-diseases-in-allogeneic-hematopoietic-.html
See More CorMedix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email.

About CorMedix

CorMedix (NASDAQ:CRMD). is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures. The company is engaged in clinical and regulatory activities designed to support product labeling updates and broader patient access. Collaborative partnerships with dialysis providers and distributors help position CorMedix to deliver its therapies into established treatment settings.

Founded in the mid-2000s and headquartered in Piscataway, New Jersey, CorMedix operates with a lean corporate structure that leverages external manufacturing and distribution networks. The company’s senior management team is led by President and Chief Executive Officer Craig Fraser, who brings more than 30 years of experience in the biopharmaceutical industry. CorMedix continues to pursue regulatory milestones and commercial arrangements that aim to expand its reach across North America, Europe and select emerging markets.

View CorMedix Profile
Earnings Tools